Enlivex Therapeutics (Israel) Today
| ENLV Stock | ILA 517.20 9.40 1.79% |
Performance0 of 100
| Odds Of DistressLess than 38
|
Enlivex Therapeutics is trading at 517.20 as of the 17th of April 2024, a -1.79% down since the beginning of the trading day. The stock's open price was 526.6. Enlivex Therapeutics has about a 38 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Enlivex Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 18th of March 2024 and ending today, the 17th of April 2024. Click here to learn more.
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel. ENLIVEX THERAPEUTI operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. The company has 18.41 M outstanding shares. More on Enlivex Therapeutics
Moving together with Enlivex Stock
| 0.67 | BTX | Lineage Cell Therapeutics | PairCorr |
| 0.62 | CBI | Clal Biotechnology | PairCorr |
Moving against Enlivex Stock
| 0.6 | LPSN | LivePerson | PairCorr |
| 0.44 | BLRX | BioLine RX | PairCorr |
| 0.43 | KTOV | Purple Biotech | PairCorr |
| 0.41 | PPBT | Purple Biotech | PairCorr |
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Enlivex Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Enlivex Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Enlivex Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Dror Mevorach |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Enlivex Therapeutics (ENLV) is traded on Tel Aviv Stock Exchange in Israel and employs 71 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 273.23 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Enlivex Therapeutics's market, we take the total number of its shares issued and multiply it by Enlivex Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Enlivex Therapeutics operates under Healthcare sector and is part of Biotechnology industry. The entity has 18.41 M outstanding shares.
Enlivex Therapeutics has accumulated about 90.6 M in cash with (17.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95.
Check Enlivex Therapeutics Probability Of Bankruptcy
Ownership AllocationEnlivex Therapeutics retains a total of 18.41 Million outstanding shares. Enlivex Therapeutics shows 12.19 percent of its outstanding shares held by insiders and 9.53 percent owned by other corporate entities. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Enlivex Ownership Details
Enlivex Stock Price Odds Analysis
What are Enlivex Therapeutics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Enlivex Therapeutics jumping above the current price in 90 days from now is close to 99%. The Enlivex Therapeutics probability density function shows the probability of Enlivex Therapeutics stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon Enlivex Therapeutics has a beta of -0.2002 suggesting as returns on the benchmark increase, returns on holding Enlivex Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Enlivex Therapeutics is likely to outperform the market. Additionally, enlivex Therapeutics has an alpha of 0.842, implying that it can generate a 0.84 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Enlivex Therapeutics to move above the current price in 90 days from now is close to 99 (This Enlivex Therapeutics probability density function shows the probability of Enlivex Stock to fall within a particular range of prices over 90 days) .
Enlivex Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Enlivex Therapeutics market risk premium is the additional return an investor will receive from holding Enlivex Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Enlivex Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Enlivex Therapeutics' alpha and beta are two of the key measurements used to evaluate Enlivex Therapeutics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 6.32 | |||
| Semi Deviation | 11.72 | |||
| Standard Deviation | 11.69 | |||
| Variance | 136.55 |
Enlivex Stock Against Markets
Picking the right benchmark for Enlivex Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Enlivex Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Enlivex Therapeutics is critical whether you are bullish or bearish towards Enlivex Therapeutics at a given time. Please also check how Enlivex Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Enlivex Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
Enlivex Therapeutics Corporate Executives
Elected by the shareholders, the Enlivex Therapeutics' board of directors comprises two types of representatives: Enlivex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enlivex. The board's role is to monitor Enlivex Therapeutics' management team and ensure that shareholders' interests are well served. Enlivex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enlivex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shachar Shlosberger | Chief Financial Officer | Profile |
How to buy Enlivex Stock?
Before investing in Enlivex Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Enlivex Therapeutics. To buy Enlivex Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Enlivex Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Enlivex Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Enlivex Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Enlivex Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Enlivex Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.
Already Invested in Enlivex Therapeutics?
The danger of trading Enlivex Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Enlivex Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Enlivex Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Enlivex Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Enlivex Therapeutics is a strong investment it is important to analyze Enlivex Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Enlivex Therapeutics' future performance. For an informed investment choice regarding Enlivex Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Enlivex Stock refer to our How to Trade Enlivex Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Enlivex Stock analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |